Director at Corcept Therapeutics (NASDAQ: CORT) receives 12,500-share option grant

Rhea-AI Filing Summary

Corcept Therapeutics director Gregg H. Alton received a new stock option award covering 12,500 shares of common stock. The options have an exercise price of $59.69 per share and expire on May 21, 2036, providing long-term equity-based compensation.

The grant vests ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, and each vesting tranche is conditioned on his continued service as of the relevant monthly vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Alton Gregg H

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	12,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 12,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 12,500 options Exercise price: $59.69 per share Expiration date: May 21, 2036 +2 more

5 metrics

Option grant size 12,500 options Stock Option (right to buy) granted to director

Exercise price $59.69 per share Conversion or exercise price for the stock options

Expiration date May 21, 2036 Option term end date

Underlying shares 12,500 shares Common stock underlying the option grant

Post-grant derivative holdings 12,500 options Total derivative securities following this grant

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vesting date

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 59.6900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting date financial

"subject to the Reporting Person's continued service on each monthly vesting date."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alton Gregg H

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$59.69	05/21/2026		A		12,500		(1)	05/21/2036	Common Stock	12,500	$0.00	12,500	D

Explanation of Responses:

1. Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Gregg H. Alton	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Corcept Therapeutics (CORT) report for Gregg H. Alton?

Corcept Therapeutics reported a grant of stock options to director Gregg H. Alton for 12,500 shares of common stock. This compensation award gives him the right to buy shares at a fixed exercise price if vesting and service conditions are met.

How many Corcept Therapeutics (CORT) shares are covered by the new option grant?

The new option grant covers 12,500 shares of Corcept Therapeutics common stock. These options provide potential future ownership, subject to vesting over one year starting May 21, 2026 and continued service on each monthly vesting date.

What is the exercise price of Gregg H. Alton’s Corcept (CORT) stock options?

The stock options granted to Gregg H. Alton have an exercise price of $59.69 per share. This means he can purchase Corcept Therapeutics common stock at that price once the options vest and before they expire on May 21, 2036.

When do Gregg H. Alton’s Corcept Therapeutics (CORT) options expire?

The granted stock options expire on May 21, 2036. Alton must exercise any vested options before this expiration date; otherwise, the right to purchase Corcept Therapeutics common stock at the fixed $59.69 exercise price lapses.

How do the Corcept (CORT) stock options granted to Gregg H. Alton vest?

The options vest ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period. Each monthly vesting is conditioned on Alton’s continued service through the respective vesting date, aligning compensation with ongoing board service.

Is Gregg H. Alton’s Corcept (CORT) option grant an open-market purchase or compensation award?

The transaction is a compensation-related grant, categorized as a "Grant, award, or other acquisition" of stock options. No open-market purchase occurred; instead, Corcept Therapeutics awarded options as part of his director compensation package on specified terms.